Application of reverse transcription polymerase chain reaction for analysis of multidrug resistance in patients with acute myeloblastic leukemia

Journal of B.U.ON.

Volumn 7, Issue 4, 2002, Pages 355-359

  Balatzenko, Gueogui ^a   Stoimenov, A ^a   Guenova, M ^a   Galabova, I ^a   Ganeva, P ^a   Hodjadjik, D ^a   Toshkov, S ^a  

^a National Center of Hematology and Transfusiology   (Bulgaria)

Author keywords

Acute myeloid leukemia; MDR1; Multidrug resistance; Polymerase chain reaction

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC LINKAGE; GENETIC SCREENING; GENETIC TRAIT; HUMAN; MALE; MULTIDRUG RESISTANCE; OUTCOMES RESEARCH; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

EID: 0038664319     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. McKenna SL, Padua RA. Multidrug resistance in leukemia. Br J Haematol 1997; 96:659-674.
2. Covelli A. Modulatio of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 1999; 10 (Suppl 6): 53-59.
3. Marie JP, Huet S, Faussat AM et al. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris. Leukemia 1997; 11: 1086-1094.
4. Szakacs G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 1998; 4: 251-257.
5. Grunebach F, Griese E-U, Schumscher K. Competitive nested polymerase chain reaction for quantification of human MDR1 gene expression. J Cancer Res Clin Oncol 1994; 120: 539-544.
6. Veelken H, Licht T, Lais A et al. Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement. Leuk Res 1998; 22: 1021-1027.
7. Kwok S, Higushi R. Avoiding false positives with PCR. Nature 1989; 339: 237-238.
8. Sonneveld P, Wiemer E. Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Leukemia 1997; 11: 1160-1165.
9. Svoboda-Beusan I, Kusek R, Bendelja K et al. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 2000; 85: 1261-1267.
10. Chevillard S, Viekh Ph, Validire P et al. French multicentric evaluatio of mdr1 gene expression by RT-PCR in leukemia and solid tumors. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunochemistry in solid tumors. Leukemia 1997; 11: 1095-1106.
11. Dalton WS. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia 1997; 11: 1166-1169.
12. Wuchter C, Karawajew L, Ruppert V et al. Clinical significance of P-glycoprotei expression and function to response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711-721.
13. Legrand O, Perrot JY, Simoni G, Baudard M, Marie JP. JC-1: A very sensitive fluorescent probe to test Pgp activity in adult acute myoeloid leukemia. Blood 2001; 97: 502-508.
14. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 1999; 94: 1086-1099.
15. Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083-1091.
16. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323-2239.
17. Tokura Y, Shikami M, Miwa H et al. Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells. Leuk Res 2002; 26: 29-36.
18. Takeshita A, Shinjo K, Ohno R. New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate. Jpn J Cancer Res 1995; 86: 607-615.
19. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods. Leukemia 1997; 11: 1067-1072.
20. Stasi R, Venditti A, Del Poeta G et al. Intensive treatment of patients 60 years of age and older with de novo acute myeloid leukemia. Analysis of prognostic factors. Cancer 1996; 77: 2476-2488.